Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819487 | 0.90 | PIK3CA (0.69) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2469732 | 0.89 | PIK3CA (0.60) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2493156 | 0.88 | PIK3CA (0.63) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2472664 | 0.87 | PIK3CA (0.51) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2470258 | 0.86 | PIK3CA (0.53) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2473327 | 0.86 | PIK3CA (0.51) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2468203 | 0.83 | PIK3CA (0.52) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2472021 | 0.83 | PIK3CA (0.50) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2466064 | 0.81 | PIK3CA (0.50) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2472630 | 0.81 | PIK3CA (0.50) | PIK3CAROCK2PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | claimed |